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ABSTRACT: Clofazimine is an antimycobacterial agent that
is routinely used for the treatment of leprosy. Clofazimine has
also been shown to have high clinical potential for the
treatment of many Gram-positive pathogens, including those
that exhibit high levels of antibiotic resistance in the medical
community. The use of clofazimine against these pathogens
has largely been limited by the inherently poor water solubility
of the drug substance. In this work, the possibility of
repurposing and reformulating clofazimine to maximize its
clinical potential is investigated. To achieve this, the potential
of novel salt forms of clofazimine as supersaturating drug-
delivery vehicles to enhance the aqueous solubility and
gastrointestinal solubility of the drug substance was explored.
The solution properties of seven novel salt forms, identified during an initial screening process, were examined in water and in a
gastrointestinal-like media and were compared and contrasted with those of the free base, clofazimine, and the commercial
formulation of the drug, Lamprene. The stability of the most promising solid forms was tested, and their bioactivity against
Staphylococcus aureus was also compared with that of the clofazimine free base and Lamprene. Salts forms which showed superior
stability as well as solubility and activity to the commercial drug formulation were fully characterized using a combination of
spectroscopic techniques, including X-ray diffraction, solid-state NMR, and Fourier transform infrared spectroscopy.
■ INTRODUCTION
Antimicrobial resistance (AR) is a prominent global threat
which has been accelerated by decades of constant selection
pressures from the human use of antibiotic resources.1−3 It has
been estimated that if action is not taken to slow the spread of
AR, the financial cost to the global economy between now and
2050 will be around $100 trillion as well as result in the loss of
countless human lives.4,5 AR has resulted in the emergence of
multidrug resistant (MDR) strains of dangerous pathogens,
such as Mycobacterium tuberculosis (MDR-TB) and Staph-
ylococcus aureus,1−3 as well as an increase in drug resistance
among bacteria that cause common healthcare-associated
infections (HAIs).1−3 HAIs are largely the product of 19
pathogens that have developed worrying levels of resistance and
are now capable of causing serious and difficult-to-treat
infections.1 Six of these pathogens are known by the acronym
“ESKAPE” and are the most common cause of life-threatening
nosocomial infections amongst the critically ill and immuno-
comprised.5−9
There have been many suggestions on how best to tackle the
looming AR problem, and the generation of novel antimicrobial
agents with new and specific modes of actions is often
suggested as the solution.10 Such an approach is likely to take
decades for sufficient numbers of new antimicrobial drug
substances to be identified and to get regulatory approval to
treat the ever increasing number of pathogens that are showing
dangerous levels of resistance.6 A more immediate strategy is to
repurpose existing drug substances to fill the antibiotic
discovery void until new treatments become available.6 This
has proven successful in the past, for example, with the
administration of β-lactamases inhibitors, such as clavulanic
acid, along with β-lactamases antibiotics such as amoxicil-
lin.6,11,12 Recently, researchers have begun to screen libraries of
Food and Drug Administration (FDA) approved drugs against
biological threats in vitro. Madrid et al. screened 1012
regulatory-approved drugs against various viral and bacterial
agents, resulting in the identification of 333 unique hits,13
Chopra et al. identified five compounds that showed significant
antibiotic activity against drug-resistant Acinetobacter bauman-
nii,14 and Kim et al. discovered 15 approved drugs that were
able to kill Candida albicans in vitro, one of which showed a
wide spectrum of antimicrobial activity.15
Clofazimine (CFZ) is an antimicrobial drug that is currently
employed as part of the World Health Organization’s (WHO)
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triple drug regimen for the treatment of leprosy.16 CFZ is
known to exhibit good in vitro activity against most Gram-
positive bacteria species, including strains that are multidrug
resistant, with minimum inhibitory concentrations (MICs) in
the range 0.5−2 mg/L in most cases.17 Gram-negative bacteria,
on the other hand, are uniformly resistant to CFZ.17,18 Gram-
positive bacteria susceptible to CFZ include the aforemen-
tioned ESKAPE pathogens, Enterococcus faecium and S. aureus,
as well as several pathogens which contribute to HAIs, namely
Clostridium difficile, Enterococcus faecalis, Staphylococcus epider-
mis, and Streptococcus pneumoniae.17−24 CFZ is also categorized
as a group 5 medicine for the treatment of extensively drug-
resistant TB and is included on the WHO list of essential
medicines for both adults and children.17,25,26 The clinical use
of CFZ in the treatment of many pathogens has been greatly
limited due to its poor aqueous solubility (<0.01 mg/
L).16,17,27,28 The limited water solubility and high lipophilicity
(log P = 7.66) of CFZ result in the accumulation of this drug
substance in fatty tissue.27,29−31 However, the antimicrobial
potential of CFZ has resulted in a renewal of interest in the
drug in recent times, and in 2016 CFZ was re-patented for the
treatment of Clostridium difficile infections in humans.32,33
Despite the reports of good activity in vitro, CFZ has
consistently performed poorly in vivo.17 For example, CFZ
has never been successfully used in the treatment of MDR-TB
despite being reportedly active against the pathogen in vitro
and being recommended by the WHO to this end.17,28 To
overcome the poor water solubility of CFZ, in vitro bioactivity
assays are usually carried out using dimethyl sulfoxide (DMSO)
as a solubilizing agent.17,19,23,28,34−37 Thus, the poor correlation
between in vitro and in vivo activities is likely related to the
poor water solubility of CFZ. If the aqueous solubility of CFZ
could be improved, then the therapeutic potential of this drug
substance might be reached in vivo.
Formulation strategies to improve solubility are broadly
characterized as either solubilizing strategies (i.e., formulation
with solubilizing agents) or supersaturating drug-delivery
systems (SDDS).38,39 The latter involves the administration
of high-energy solid forms, such as amorphous solids,
crystalline salts or cocrystals and allows the generation of
supersaturated solutions.38,39 The main disadvantage of these
systems is their tendency to precipitate from solution and to
revert to the equilibrium solubility of a more stable solid
form.38,39 Several previous attempts to address the aqueous
solubility of CFZ have been made with varying degrees of
success. These included solubilizing strategies, such as the
formulation of CFZ with bile salts,40 encapsulation of the drug
into liposomes,41,42 formulation with water-soluble polymer
carriers,43−45 conjugation onto modified cyclodextrin,46 and
formulation as amorphous solid dispersions.47 The failure of
these previous studies was likely due to the large hydrophobic
structure of the CFZ molecules, and it associated inherently
poor aqueous solubility. Of the various SDDS approaches, the
use of crystalline salts is arguably the most well known. In the
pharmaceutical industry, salt formation has become a
commonly applied technique for increasing solubility and
dissolution rates during the drug product development
process.48 The resulting crystalline salts dissociate in solution
to form ionized species that are more soluble in water
compared to the unionized molecules.38,48 Even without
crystallization inhibitors, pharmaceutical salts often generate
supersaturation levels where precipitation out of solution is
slow enough to improve drug bioavailability.49 CFZ itself is a
weak base (pKa = 8.511
29) and has previously been shown to
readily form salts with a variety of acid coformers and with
Scheme 1. Schematic Description of the Screening Procedure To Select Solid Forms Based on Solubility in Aqueous Media, in
Fasted-State Simulated Gastric Fluid (FaSSGF) and in Fasted-State Simulated Intestinal Fluid (FaSSIF)a
aStep 1: screening CFZ for salt formation in various 1 M acidic solutions, isolation and monitoring of the solid phase present via vacuum filtration
and PXRD. Step 2: determination of the supersaturation profile of the new solid form in deionized water, FaSSGF, and FaSSIF, followed by isolation
and monitoring of the solid phase present via vacuum filtration and PXRD.
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acidic polymers forming ionic solid dispersions.50,51 The salts
were characterized, and their solution properties were studied
in a dissolution medium of ethanol and water. This choice of
media may have been due to the poor aqueous solubility of
these CFZ salts, and the choice of counterion had no apparent
rationality. In this study, the optimal solid form of CFZ is
isolated based on its solubility and supersaturation in water and,
more importantly, in a gastrointestinal-like environment. This
should maximize the potential of the resulting solid form to
increase absorption in the gastrointestinal tract and thus
improve the bioavailability of the drug.
■ RESULTS AND DISCUSSION
To improve the aqueous solubility of CFZ, a systematic
screening process for new salt forms of the drug was developed
based on supersaturation potential in water and in gastro-
intestinal-like media (Scheme 1). Acid coformers were selected
such that ΔpKa, the difference between the pKa values of the
acid coformers and that of CFZ (pKa = 8.511
29), remained
greater than 2 pKa units (Table 1). This is in keeping with the
hypothesis that if ΔpKa is greater than 2, salt formation
occurs.50,52 During these slurry experiments, the formation of a
novel solid phase was confirmed by powder X-ray diffraction
(PXRD) (Figure 1).
Solution Properties of CFZ Solid Forms in Water.
Following the identification of these new solid forms via PXRD,
their melting points and solution properties in deionized water
were studied (Figure 2, Table 2). From these supersaturation
profiles values for maximum supersaturation (Smax), the time to
reach Smax (tSmax) and initial dissolution rate (D
initial) were
obtained and are compared in Table 2. In deionized water, each
new solid form of CFZ increased the aqueous concentration of
CFZ, whereas the CFZ polymorphs or the commercial
formulation (Lamprene) did not dissolve to any detectable
extent (detection limit < 0.1 mg/L) (Figure 2). The order of
supersaturation (relative to CFZ F III) for these salts observed
in deionized water was seen to be phosphate > sulfate > acetate
> formate > citrate > oxalate > nitrate > chloride ≫ CFZ (free
base)/Lamprene. Following the dissolution of the various solid
forms, de-supersaturation and precipitation occurred, removing
CFZ from solution. The rate of precipitation from solution
differed depending on the solid form administrated and the
resulting supersaturation level in solution. For each new solid
form administered to deionized water, the solid form
precipitating out of solution was always found to be the
triclinic polymorph of CFZ, F I (Figure 3). Crystallization of
CFZ F I can only happen following the deprotonation of the
CFZH+ solution species back to the unionized free base species,
CFZ. Thus, the rate of precipitation likely depends on the rate
at which CFZH+ converts back to CFZ. The unprotonated
CFZ species is highly insoluble in water and therefore there is a
strong driving force for it to crystallize. Interestingly, of the four
CFZ polymorphs known, CFZ F I is the least thermodynami-
cally stable and thus the first available crystal structure,
according to the Oswald rule of stages.53
Solution Properties of CFZ Solid Form in FaSSGF. The
solid forms with the best aqueous solubility, i.e., sulfate,
phosphate, citrate, formate and acetate, were then screened for
supersaturation potential in fasted-state simulated gastric fluid
(FaSSGF), where they were once again compared with CFZ F I
and the commercial formulation, Lamprene. From these
supersaturation profiles, values for Smax, tSmax, and D
initial were
obtained for FaSSGF and are also presented in Table 2. The
maximum supersaturation in FaSSGF followed the order,
phosphate > sulfate > citrate > acetate > Lamprene > formate >
CFZ F I, and these results are shown in Figure 4. In the
FaSSGF media, there was also a stark reduction in the amount
of CFZ that could be held in solution, or Smax, compared to that
Table 1. List of Coformers Used in Solid Form Screening,
Their pKa Values, and ΔpKa Relative to CFZa
coformers pKa ΔpKaa abbreviation
hydrochloric acid <−6 14.511 HCl
sulfuric acid −3 11.511 Sul
nitric acid −1.3 10.211 Nit
oxalic acid 1.27 7.241 Oxa
phosphoric acid 2.12 6.391 Pho
citric acid 3.1 5.411 Cit
formic acid 3.75 4.761 For
acetic acid 4.76 3.751 Ace
apKa CFZ taken as 8.511, as determined at 37 °C.
29
Figure 1. Comparison of PXRD diffractograms of the various CFZ
polymorphs with the solid form present in solutions following slurry
experiments.
Figure 2. Comparison of the dissolution profiles of CFZ salt forms in
deionized water at 37 °C and 150 rpm.
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in deionized water (Table 2). The phosphate and sulfate salts,
which reach concentrations as high as 104 and 82 mg/L
respectively, in deionized water, struggled to surpass 20 mg/L
in FaSSGF, and the stability of the resulting solutions was poor
(Figure 4, Table 2). This apparent supersaturation limit of ∼20
mg/L was common across all novel salts of CFZ administered
to FaSSGF media (Figure 4). Moreover, regardless of which
solid form of CFZ was administered into the FaSSGF, the solid
form which precipitated out of solution was found to be a
hydrochloride salt of CFZ (Figure 3). The driving force for the
observed conversion into the hydrochloric acid salt is likely the
high chloride concentration of the FaSSGF. The fact that the
CFZ F I also converts to the hydrochloric acid salt suggests that
this salt form is a more thermodynamically stable crystalline
form of the drug in the high chloride content of the FaSSGF
media. De-supersaturation and crystallization from solution
happened much faster for the salts in FaSSGF as compared to
deionized water, and again this is likely due to the high chloride
concentration of the FaSSGF. These findings are in agreement
with a previous study in which this hydrochloride acid salt was
first identified and was shown to be the form in which CFZT
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Figure 3. PXRD comparison of solid form precipitating out of
solutions of FaSSGF, FaSSIF, and deionized water after 30 min,
following administration of the phosphate salt.
Figure 4. Comparison of the dissolution profiles in FaSSGF of the
CFZ salts with CFZ F I and the commercial formulation of the drug
(Lamprene).
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accumulates in animal tissues31 but contradicts dissolution
studies carried out on amorphous CFZ loaded onto silica
nanoparticles in a different gastrointestinal-like media.54 In
FaSSGF media, the phosphate and sulfate salts reached the
highest concentration but also precipitated out of solution
faster than the citrate and acetate salts (Figure 4). Solution
stability of all salts in the FaSSGF media appeared to be limited
by supersaturation. If the concentration increased above ∼20
mg/L, rapid de-supersaturation occurred (Figure 4). The citrate
and acetate salts maintain their supersaturation levels in
FaSSGF better than the sulfate and phosphate, as they do
not exceed this critical concentration threshold of ∼20 mg/L.
The rapid onset of crystallization, which repeatedly occurs
above a concentration of 20 mg/L, must be due to the
supersaturation level entering the labile zone, where sponta-
neous nucleation occurs. Thus, there appears to be an inherent
instability to solutions of CFZH+ in this FaSSGF medium at
concentrations above 20 mg/L.
Solution Properties of CFZ Solid Form in FaSSIF. One
common failure of salt forms of basic drugs is their tendency to
precipitate from solution in the more basic conditions of the
intestinal tract. The intestine is the major location for the
absorption of oral drugs, and thus dissolution and super-
saturation properties in FaSSIF are arguably more relevant than
in FaSSGF. Given the adequate stability and enhanced solution
behavior of the phosphate, sulfate and citrate salts in FaSSGF,
the solution properties of these three salts were examined in
FaSSIF, where they were compared with CFZ F I and
Lamprene (Figure 5). From their dissolution profiles, values for
Smax, tSmax, and D
initial were obtained as before and are presented
in Table 2. In FaSSIF, the citrate, phosphate and sulfate salts all
showed improved dissolution profiles compared to those of
Lamprene or CFZ F I and supersaturation in this media
followed the order, citrate > phosphate > sulfate > Lamprene >
CFZ F I. Compared to the FaSSGF media, there was a
significant reduction in the dissolution rates of the CFZ salts in
FaSSIF and a significant reduction in the amount of CFZ which
went into solution in the more basic FaSSIF (Figure 5 and
Table 2). This was, however, unsurprising, as the fast
dissolution rates associated with salt forms of basic drugs is a
result of differences in the pH of the diffusion layer of the salt
and the pH of the bulk media.55 If the latter is changed, then
the dissolution rate of the salt in that media will consequently
change. It was found to be CFZ F I, or the basic form of the
drug, that precipitated from solution in the FaSSIF and not the
chloride salt, as was the case in the lower pH FaSSGF media.
This was unsurprising as significant work has been done to
show how salts of basic drugs will convert to and precipitate
from solution as their respective free bases above some
theoretical pH value, termed pHmax.55 In the FaSSGF media,
the high chloride concentration and fast dissolution rate of the
salts result in a critical concentration of CFZH+ being reached
around ∼20 mg/L, which results in rapid de-supersaturation.
However, in the FaSSIF media, the maximum solution
concentration reached was ∼10 mg/mL and thus de-super-
saturation occurs slower even though the chloride concen-
tration is higher. Chlorine concentration in the FaSSIF appears
to have no effect on solution stability as it is CFZ F I and not
the hydrochloride salt of CFZ which precipitates. Thus, the
crystallization of CFZ F I from solution in FaSSIF is not driven
by the common ion effect, as was the case in FaSSGF.
Antimicrobial Activity of Novel Salts. The antimicrobial
activity of CFZ F I was compared to that of the salts that
exhibited acceptable solution properties in FaSSGF and FaSSIF
and long-term stability, i.e., the phosphate, sulfate, and citrate
salts. These solid forms were tested for activity against S. aureus,
and this data is presented in Figure 6. As mentioned previously,
CFZ is routinely used in the treatment of leprosy; however, it
has also been reported to display activity against S. aureus at
concentrations of less than 5 μg/mL,23,56 albeit in the presence
of DMSO, which acts as a solubilizing agent. During the
microtiter activity studies of CFZ F I and the citrate, phosphate,
and sulfate salts, varying degrees of inhibition of bacterial
growth against S. aureus were observed. There was no inhibition
of bacterial growth from bacteria incubated in the presence of
CFZ F I at either 20 or 40 μg/mL (Figure 6). Bacterial growth
initially was slower with the citrate salts for up to ∼8 h;
however, final populations were similar in numbers to those of
the control and therefore no MIC50 was determined (Figure 6).
Similarly, initial growth of the bacteria in the presence of the
sulfate salt at 20 μg/mL was much lower than that of the
control; however, final populations after 24 h were similar
(Figure 6). The sulfate salt caused a significant decrease in
Figure 5. Comparison of the dissolution profiles in FaSSIF of CFZ
salts with CFZ F I and the commercial formulation of the drug
(Lamprene).
Figure 6. Activity of CFZ F1 and citrate, phosphate and sulfate salts
against S. aureus at 20 and 40 μg/mL. Cultures were incubated with
the drugs for 24 h at 37 °C.
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bacterial population when compared to that of the control at 24
h, giving an MIC50 of 40 μg/mL. In the case of the phosphate
salts, an MIC50 was established at 20 μg/mL over the 24 h
analysis when compared with the control (Figure 6). Although
not all of the salts exhibited sufficient killing for the
determination of a MIC50 value, each of them showed an
improvement in activity against S. aureus when compared with
CFZ F I. Indeed, without DMSO present in the assay to
solubilize the CFZ, no activity was noted against S. aureus for
the free base. There is a trend in the literature where
antimicrobial activity assays for hydrophobic drugs such as
CFZ are usually carried out by dissolving the drug substance in
DMSO or ethanol, thereby overcoming the hydrophobic nature
of the drug for the sake of the in vitro assay.17,19,23,28,34−37 The
results of such tests has led to a library of low MIC values for
CFZ against a range of different pathogens.17,19,23,28,34−37 Yet,
in vivo activity data has remained largely inconclusive and these
discrepancies have been alluded to in a recent review.17 The salt
forms of CFZ isolated here overcome the hydrophobic nature
of the pure drug temporarily, resulting in enhanced killing
against S. aureus.
Solid-State Characterization. The solid forms generated
in solutions with phosphoric acid, sulfuric acid, and citric acid
coformers, having the best solution properties in the FaSSGF
medium, were characterized using a combination of solid-state
nuclear magnetic resonance (SSNMR) and Fourier transform
infrared (FTIR) spectroscopy, X-ray diffraction (XRD) and
stability testing. For a new solid form to make it from the lab to
the market, it must be stable under storage conditions for
prolonged periods of time. The salts with the most promising
solubility in FaSSGF, i.e., the acetate, citrate, phosphate, and
sulfate, were exposed to the FDA-recommended accelerated
stability testing conditions.57 The results of these stability tests
are summarized in Figure 7. The phosphate, citrate, and sulfate
salts retained their respective structures under these conditions
for the duration of the test (3 months). The acetate salt did not
retain its structure during the testing and was seen to undergo a
phase transformation into the monoclinic polymorph, CFZ F
II, during the first week of the test. When a sample of the
acetate salt was heated up to around 100 °C, it was found that
acetate molecules evaporated to leave CFZ F II (Figure 8).
Thus, the acetate salt would be unlikely to have a drug delivery
application due to its poor stability and was excluded from
further studies.
Salts are defined by the transfer of a hydrogen atom from an
acid to a base and thus the formation of an ionic bond.58,59 The
challenge in characterizing a salt from a cocrystal stems from
the difficulty in clearly defining hydrogen atom positions using
XRD, although recently it has been suggested that in some
cases, hydrogen atom positions can be accurately defined to
within one standard deviation using the Hirshfeld atom
refinement computational analysis.60 Nevertheless, it is also
Figure 7. Comparison of the PXRD diffractograms of the citrate, acetate, phosphate, and sulfate salts before storage at 40 °C/75%, with
diffractograms collected after storage under these conditions for fixed times.
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possible to characterize ionic bond formation indirectly using
spectroscopic techniques, such as FTIR and NMR, as well as by
monitoring changes in the crystal structures caused by
protonation of molecules.
Crystallographic data obtained from single-crystal X-ray
diffraction (SCXRD) experiments for the citrate, sulfate and
phosphate is summarized in Table 3. For each of these salts,
there was good correlation between the experimental PXRD
diffractograms and those calculated from the single-crystal
structures (Figure 9). The crystal structures of these salts and
the previously reported CFZ polymorphs were analyzed using
the Cambridge Structural Databank (CSD) software, Mercury.
The bonding angle of the secondary ketimine groups (C
NC−C) in each crystal was measured. The bond angle C
NC−C, which undergoes protonation, was seen to increase
from around 120° in each polymorph of CFZ to around 125° in
each of the salt forms (Figure 10). However, the bond angle
C−NBC, which does not become protonated, remained
unchanged in the range 118−119° in the various solid forms.
Once protonated, the central nitrogen (NC), of the secondary
ketimine (CNC−C), develops a +1 charge and a new
coordination number of 3, which explains the observed increase
of the CNC−C bond angle by about 5°. This increase in the
bond angle was observed in the structure of each salt
characterized here and is consistent with observations made
during previous studies on the crystal structures of salts formed
between pyridine derivatives and acidic coformers.61 When
previously reported CFZ salts were analyzed in this way, a
similar increase in the CNC−C bonding angle was noted.50
FTIR and SSNMR spectroscopy were used to further
validate this salt formation hypothesis. Ionic bonds themselves
do not resonate in the presence of infrared radiation, so FTIR
spectroscopy was used to probe for a new NC
+−H bond in the
potential salt forms and to monitor the stretching of the C
NC double bond of the ketimine group. The FTIR spectra
obtained for the different CFZ polymorphs were found to be
indistinguishable (Figure S2), and thus only F III was compared
with the potential salt forms. The presence of the new NC
+−H
bond for each salt form was observable in the range 3250−3350
cm−1, and by comparison, no such peak was present in the free
base (CFZ F III) (Figure 11). Protonation of NC caused a
bathochromic shift in the peak representative of the CNC
double bond (1626.5 cm−1, in F III) to a lower wavenumber in
each salt form of CFZ (Figure 11). This movement to a lower
wavenumber indicates a weakening this CNC double bond,
giving further proof of protonation. These observations are
consistent with accounts of reported ionic bond formation
Figure 8. Comparison of the PXRD diffractograms of the CFZ-acetate
solid forms showing the effects of heat on the crystal structure.
Table 3. Summary of Crystallographic Data for CFZ Salts
solid form CFZ-Cit CFZ-Sul CFZ-Pho
crystal system triclinic monoclinic triclinic
space group P1̅ C2/c P1̅
a (Å) 14.7405(6) 18.9525(10) 14.5795(12)
b (Å) 15.8212(7) 15.4712(10) 15.6517(13)
c (Å) 16.2505(9) 20.0349(12) 28.228(2)
α (deg) 71.927(2) 90 95.326(2)
β (deg) 63.0413(13) 100.360(2) 92.101(2)
γ (deg) 70.7443(15) 90 112.174(2)
volume (Å3) 3130.3 5778.82 5921.33
Z 4 8 8
Dcald (g/cm) 1.412 1.314 1.2818
R-factor (%) 6.53 12.21 13.61
temp. (K) 283−303 283−303 283−303
Figure 9. Comparison of the calculated and experimental PXRD
diffractograms for the new salts: clofazimine citrate (black),
clofazimine sulfate (red), and clofazimine phosphate (blue).
Figure 10. Left: summary of secondary ketimine bonding angles in
CFZ solid forms calculated using Mercury software from single-crystal
cif files (average taken for solid Z′ numbers >1). Right: structure of
CFZ(−H+) with nitrogen atoms labeled.
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between CFZ and hypromellose phthalate as well as in other
salts of CFZ with acidic coformers.50,51 A comparison of the full
FTIR spectra for these solid forms can be found in the
Supporting Information (Table S1, Figure S2).
SSNMR was used to investigate changes in the chemical
shifts of the carbon atoms of CFZ following salt formation. The
peak positions of the carbon atoms in CFZ and its respective
salt forms were assigned through a combination of molecular
modeling and solution NMR. These peak assignments were in
agreement with previous studies.27,51,62 13C cross-polarization
magic-angle spinning (CPMAS) solid-state NMR spectra were
collected for the phosphate, sulfate and citrate salts as well as
CFZ F III. During these 13C CPMAS experiments, the chemical
shift of the ketimine carbons (NBC and NCC) were
monitored in the range 140−155 ppm, whereas the chemical
shift of the isopropyl carbon adjacent to NC was monitored in
the range 40−65 ppm. The resulting peak position from the
13C CPMAS spectra is shown in Figure 12. A full comparison of
the 13C CPMAS spectra for these salts with CFZ F III can be
found in the Supporting Information as well as a table of the
chemical shifts of the carbon atoms bound to the nitrogen
atoms in the secondary ketimine functional groups of CFZ, i.e.,
CNC−C and C−NBC, and their respective bond lengths
from the crystal structures of solid form (Table S2, Figure S3).
These new salts of CFZ had several drug molecules in their unit
cells, some of these being chemically inequivalent, leading to
broad or several peaks for individual carbons in the 13C
CPMAS spectra (Figure S3). In general, following salt
formation, the chemical shift of the isopropyl carbon (NC−
C) shifted upfield (Figure 12), indicating shielding of this
carbon nucleus from the magnetic field of the spectrometer.
This shielding is likely due to electron density being donated
from the adjacent methyl groups in response to the protonation
of NC. A similar upfield shift was seen for the ketimine carbon
bonded to NC (CNC) (Figure 12). This shift is expected due
to electron density migrating from the phenazine nucleus
toward the protonated nitrogen (NC
+−H), causing local
shielding of the ketimine carbon (CNC). By comparison,
the carbon atom in the conjugated ketimine (C−NBC) did
not shift upfield following protonation and was seen to be
resonant at ∼151 ppm in the four CFZ salts (Figure 12). These
observations are in agreement with previous studies where
protonation of NC in CFZ occurring from HPMCP resulted in
similar upfield shifts in the chemical shift of these ketimine
carbons.51
Thus, the increase in CNC−C bonding angle following
interaction with acidic coformers, the subsequent weakening of
the CNC bond, and presence of a new NC−H bond in the
FTIR spectra of these solid forms, as well as the shielding of
both the ketimine carbon and the isopropyl carbon adjacent to
the protonation site (CNC−C) indicate that salt formation
occurs between phosphoric acid, sulfuric acid, and citric acid
with CFZ, as was suspected from the ΔpKa of CFZ with these
acid coformers.50,52
■ CONCLUSIONS
Novel solid forms of drugs are of value provided that, compared
with the existing solid forms, their physicochemical properties
are more favorable. For many drugs, solubility and dissolution
rates are properties that will determine the drug bioavailability
in vivo, and thus being able to manipulate these properties is of
great importance. Eight salts of CFZ were identified using an in
situ salt screening approach during this work, seven of which
were novel salts, and three of these were then selected for
further characterization based on their solubility and dissolution
rates in simulated gastrointestinal fluids. The CFZ salts
exhibited fast dissolution rate and enhanced solution properties
in the low pH FaSSGF media, but there was an intrinsic
instability to supersaturated solutions of CFZH+ above ∼20
mg/L in this medium. In the FaSSIF media, each salt tested
Figure 11. Overlay of the FTIR spectra of CFZ F III with sulfate, phosphate and citrate salts, showing evidence for (a) new NC−H bond formation
in the range 3350−3250 cm−1 and (b) weakening of CNC bond following protonation in the range 1650−1600 cm−1.
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showed a much reduced dissolution rate and a lower maximum
solution concentration compared to those in FaSSGF media.
This was due to the higher pH of the FaSSIF. However, in
every case, the CFZ salts exhibited increased dissolution rates
and increased solution concentrations compared with the
commercial formulation or the basic drug. The improved
solubility profiles of the sulfate, phosphate, and citrate CFZ
salts also enhanced killing against S. aureus compared with the
free base (CFZ F I) in vitro. Thus, supersaturating delivery
systems can improve the solubility and antimicrobial activity of
CFZ in vitro but whether this is sufficient to enable the
antimicrobial potential of CFZ in vivo remains to be seen.
■ MATERIALS AND METHODS
Materials. Clofazimine (CAS registry number 2030-63-9)
was purchased from Beijing Mesochem Technology Co., Ltd.
Coformers, including hydrochloric acid (37%, Sigma-Aldrich),
sulfuric acid (95−97%, Sigma-Aldrich), nitric acid (70%, Sigma-
Aldrich), oxalic acid anhydrous (>99%, Sigma-Aldrich), ortho-
phosphoric acid (85%, Sigma-Aldrich), citric acid monohydrate
(>99%, Sigma-Aldrich), formic acid (acetic acid (>95%, Sigma-
Aldrich)), and acetic acid (99.8%, Sigma-Aldrich) were used as
received. Methanol (>99%) being of HPLC grade and used
without further purification was also purchased from Sigma-
Aldrich. Ingredients for the dissolution media; pepsin
(extracted from porcine mucosa, Amresco), sodium taurocho-
late hydrate (NaTc, >97%, Sigma-Aldrich), L-α-phosphatidyl-
choline (lecithin, ∼ 99% purity, from bovine brain, Sigma-
Aldrich), sodium chloride (Fisher Scientific), maleic acid
(>99%, Sigma-Aldrich), and hydrochloric acid (37%, Sigma-
Aldrich) were used as received from suppliers. Brain Heart
Infusion Broth (Sigma-Aldrich) was used as a medium for
bioactivity assays.
Screening for Salt Formation. Ten milliliters of 1 M acid
solution was placed into 20 mL vials along with a magnetic stir
bar and 100 mg of CFZ (F I). The resulting suspensions were
stirred at 400 rpm for 24 h, at which point the solid form was
monitored. Twenty milligrams of the solid was removed, dried
under vacuum, and then immediately analyzed using reflection
PXRD.
Preparation of Salts. One gram of CFZ (F I) and 1.2
equiv of coformer were added to a 100 mL Duran flask
containing 50 mL of methanol. The solution was slurried for 24
h and then filtered under vacuum. The resulting crystalline
powder was placed in an oven at 40 °C overnight to dry.
Growth of Single Crystals. Hundred milligrams of CFZ F
I and coformer (1:1 molar ratio) were added to 100 mL of
methanol and heated to 50 °C and stirred at 600 rpm for 1 h.
The solution was then filtered (using preheated syringe and
filter) into a second 100 mL Duran flask, which had been
preheated to 50 °C, sealed with parafilm, and pierced with a
single hole. The solution was left to cool and evaporated until
Figure 12. Comparison of the 13C CPMAS spectra obtained for the citrate, phosphate, and sulfate salts with CFZ F III (top) in the range 140−155
ppm to monitor the chemical shift of the ketimine carbons highlighted and (bottom) in the range 40−65 ppm, to monitor the chemical shift of the
isopropyl carbon highlighted.
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∼25 mL of solvent remained, which point the crystals were
harvested under vacuum.
Preparation of Simulated Body Fluid (FaSSGF and
FaSSIF). Fasted-state simulated gastric fluid (FaSSGF) was
prepared at pH 1.6 using a previously reported recipe,63 with a
small modification to control the final chloride-ion concen-
tration. The final composition of the FaSSGF consisted of
pepsin (0.1 mg/mL), sodium taurocholate (80 μM), lecithin
(20 μM), sodium chloride (7.2 mM), and hydrochloric acid (25
mM). Fasted-state simulated intestinal fluid (FaSSIF) was
prepared at pH 6.5, in accordance with a recipe previously
reported by Marques et al.64 The final composition of the
FaSSIF consisted of sodium taurocholate (3 mM), lecithin (0.2
mM), maleic acid (19.12 mM), sodium hydroxide (34.8 mM),
and sodium chloride (68.62 mM).
Supersaturation Studies on CFZ Solid Forms. Dis-
solution experiments were carried out in deionized water,
FaSSGF, and FaSSIF. These experiments were conducted in
100 mL Duran flasks containing poly(tetrafluoroethylene)
(PTFE) stir bars and 100 mL of dissolution medium. Solutions
were stirred at 150 rpm on a submersible stir plate in a water
bath at 37 °C. All samples were ground and passed through
particle size sieves (Fisher scientific) to obtain a particle size
distribution of 63−90 μm. Following grinding and sieving of
the solids, reflection PXRD confirmed no change in their solid
form. For the dissolution experiments, samples containing 20
mg of CFZ were added to the dissolution medium. The flask
was inverted several times due to the poor wettability of CFZ.
Samples were withdrawn at predetermined time intervals using
preheated (40 °C) 5 mL syringes and hypodermic needles and
then filtered using preheated (40 °C) PTFE syringe filters (0.2
μm, 25 mm diameter, Fisher Scientific). The CFZ concen-
tration was then immediately determined using a double beam
UV−vis spectrophotometer (Shimadzu, UV-1800) at a
detection wavelength of 488 nm. For calibration of the
instrument, standard solutions were prepared in the concen-
tration range 0.1−20 mg/L and good linearity was observed (R2
> 0.999).
Slurry Experiments to Monitor Solid Form. Slurry
experiments were carried out in the various dissolution media
to determine the solid phase present during and after the
dissolution experiments. Fifty milligrams of the solid sample
was added to 20 mL of the dissolution medium to mimic
supersaturation conditions of the dissolution experiments. This
was inverted several times and then stirred on a submersible stir
plate at 150 rpm and 37 °C. Solid samples were removed via
filtration under vacuum at predetermined time points and
characterized by reflection PXRD.
Stability Testing of Optimal Salt Forms. Accelerated
stability testing was carried out for selected CFZ salts at 40 °C/
75% relative humidity in a sealed humidity chamber. Glass vials,
without caps, containing 20−30 mg of a salt were kept in the
humidity chamber and then removed at intervals of 1, 2, 4, 8,
and 12 weeks. Upon removal, each solid sample was
characterized via PXRD, where full retention of the PXRD
pattern indicated compound stability.
Antibacterial Activity Assays. The minimum inhibitory
concentration (MIC) against S. aureus (DSMZ 20231) was
calculated using a microtiter assay. More specifically, the
minimum concentration required to kill 50% of the bacterial
population, the MIC50, in this case after 24 h, was calculated.
An overnight culture was grown up in Brain Heart Infusion
Broth at 37 °C, shaking at 250 rpm. First, the CFZ F I and CFZ
salts were dissolved/suspended in water and shaken at room
temperature for 10 min. Following this, the drug solution/
suspension was added to a 96-well plate to give a final
concentration of 20 or 40 μg/mL of CFZ in each well. Sterile
water was added to each well to bring the volume to 20 μL.
Then, 180 μL of the diluted bacterial culture (OD = 0.1) was
added, so the total volume in each well was 200 μL. Blanks
were set up with media only and media plus different test
concentrations of each salt. Control wells were also set up with
bacterial culture only. The 96-well plates were incubated in a
Biotek ELx808 Ultra microplate reader (Mason Technologies,
Dublin, Ireland) at 37 °C for 24 h, and wavelength was read at
590 nm. The plate was shaken mildly before each reading, and
readings were taken every 30 min. Three wells were set up for
each test concentration, control and blank.
■ SOLID-STATE CHARACTERIZATION
Powder X-ray diffraction (PXRD) was performed using an
Empyrean diffractometor (PANalytical, Phillips) in reflection
mode, with Cu Kα radiation (γ = 1.5406 Å) operating at 40 kV
and 40 mA and at room temperature. Samples were scanned
from 4 to 35° (2θ) at 4 rpm and scan conditions of a scan step
size of 0.0131° (2θ) and 48.195 s per step.
Single-crystal X-ray diffraction (SCXRD) measurements
were collected at room temperature (299.86 K), on a Bruker
Quest D8 Mo Sealed Tube (λ = 0.71073 Å), equipped with a
CMOS Photon Detector. Data were corrected for absorption
using empirical methods (SADABS) based upon symmetry-
equivalent reflections combined with measurements at different
azimuthal angles. Crystal structures were solved and refined
against all F2 values using the SHELX interfaced with the X-
SEED program. Nonhydrogen atoms were refined anisotropi-
cally, and hydrogen atoms were placed in calculated positions
refined using idealized geometries (riding model) and assigned
fixed isotropic displacement parameters.
Melting points of solid forms were determined using a Stuart
melting point apparatus (SMP10). Solid samples in the size
range 63−90 μm were added into capillary tubes and heated
until melting was observed.
Fourier transform infrared (FTIR) spectra of the solid
samples were collected on a PerkinElmer Spectrum 100 FTIR
spectrometer equipped with a Universal ATR sampling
accessory (single reflection and diamond/zinc selenide materi-
al). Spectra for each solid form were collected at room
temperature using an average of 32 scans and a spectral
resolution of 4 cm−1 in the spectral region 4000−650 cm−1.
Carbon-13 solid-state nuclear magnetic resonance (SSNMR)
spectra were acquired on a Bruker Avance III HD NMR
spectrometer operating at B0 = 9.4 T, with corresponding
1H
and 13C resonance frequencies of ν0(
1H) = 400.1 MHz and
ν0(
13C) = 100.6 MHz. CFZ solid forms were packed in 4 mm
o.d. zirconia rotors with Kel-F caps under ambient atmosphere,
and experimental 13C NMR spectra were acquired at natural
abundance using a 4 mm triple channel (H/X/Y) Bruker MAS
probe operating in double resonance mode. The magic angle
was optimized using a rotor packed with KBr and spun at 5
kHz. NMR spectra were referenced to TMS at δiso = 0 ppm by
setting the high frequency 13C resonance in adamantane to
38.48 ppm.65 The 13C CPMAS NMR spectra were acquired in
a single spectral window using the cross-polarization pulse
sequence, with a magic-angle spinning (MAS) rotor frequency
of 10 kHz, a 1H 90° pulse width of 2.5 μs, and 50 kHz 1H
decoupling during acquisition. Proton decoupling was carried
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out with the SPINAL6466 decoupling sequence at 100%. For
each sample, the 1H T1 relaxation time(s) were checked using
the saturation recovery pulse sequence to ensure that the
recycle delay allowed for adequate relaxation between the
collection of subsequent transients. 13C CPMAS spectra were
collected using optimized contact times (2.5 μs) and relaxation
delays (at least 1.4 × T1 values) for each sample. The optimized
parameters for CFZ F III were a contact time of 2 ms,
relaxation delay of 6 s, and 128 scans; for CFZ phosphate,
contact time was 3 ms, relaxation delay 2 s, and 500 scans; for
CFZ citrate, contact time was 4 ms, relaxation delay 7 s, and
500 scans; for CFZ sulfate, contact time was 1 ms, relaxation
delay 3 s, and 500 scans.
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